On March 1, 2019, AMCP provided comments to CMS in response to its 2020 for Medicare Part D Call Letter. AMCP offered comments on the following sections of the notice; Part D Benefit Parameters for Non-Defined Standard Plans; Formulary Submissions; Medication Therapy Management (MTM); and Part D Mail Order Auto-Ship Modifications.
AMCP shares concern about the rising costs of medications and the impact on patients, payers, and providers. In 2017, AMCP identified three key areas where AMCP members help to improve health outcomes and lower costs. These areas focus on enhancing value for outcomes; enhanced approaches to medication coverage determinations; and market competition for generics and biosimilars to lower costs.
Payer reimbursement pressures are leading to radical changes in the oncology treatment, but there is a need for improved guidance for providers in assessing drug value, according to an article in JMCP.
A literature review published in JMCP found mixed evidence regarding the use of pharmacogenomic testing to guide cancer treatment. Prioritization of clinically relevant drug-gene associations is critical in determining which tests are beneficial.